2014


To access this material please log in or register

Register Authorize
2014/№2

Hyperglycemia at hospitalization of patients with ST-segment elevation myocardial infarction as a marker for unfavorable prognosis

Panina A. V., Dovgalevsky Ya. P., Dolotovskaya P. V., Furman N. V., Puchinjyan N. F.

Keywords: hyperglycemia, ST-segment elevation myocardial infarction, prognosis, risk factors

DOI: 10.18087/rhj.2014.2.1887

Background. The role of hyperglycemia in development of cardiovascular complications in patients with acute ST-segment elevation MI (STEMI) is still not completely clear. Aim. To evaluate the significance of glycemia at admission as a predictor of complications and unfavorable outcome in patients with STEMI in the absence of DM. Materials and methods. The study included 335 patients (259 males and 76 females) admitted to the emergency cardiology department for STEMI. All patients were divided into groups based on the history of DM: patients without DM (301 patients) and with DM (34 patients including patients with newly diagnosed DM). For evaluation of the effect of glycemia on the STEMI course and prognosis, patients without DM were subdivided into 2 subgroups based on the blood glucose level at admission: with blood glucose <6.1 mmol / l (270 patients) and ≥6.1 mmol / l (31 patients). Results. The presence of DM was associated with a significantly higher risk of death during hospitalization compared to patients without DM irrespective of the blood glucose level at admission (OR, 6.6 [95 % CI, 1.75–24.5], р=0.0052). The same was true for patients with impaired glucose metabolism including DM or hyperglycemia at admission (combined groups 1b and 2) compared to patients without DM or hyperglycemia (group 1a) [OR, 6.76 (95 % CI, 1.85–24.7), р=0.0038]. Patients with hyperglycemia at admission (group 1b) had higher risk of fatal outcome during hospitalization than patients with normoglycemia and without DM (group 1а) [OR, 4.6 (95 % CI, 0.8–26.1), р=0.078]. Patients with increased blood glucose levels and patients with earlier documented DM were not significantly different in the long-term prognosis although all-cause death, recurrent MI, unstable angina, and acute HF were somewhat more frequently observed in patients without DM and with hyperglycemia at admission within one year after the discharge from the hospital. Conclusion. Obviously, MI patients with hyperglycemia at admission without DM should be considered at high risk for complications and unfavorable outcome. Evaluation for hyperglycemia at admission of a STEMI patient without DM apparently can be used as an additional factor for risk stratification.
  1. Каретникова В. Н., Беленькова Ю. А., Зыков М. В. и др. Уровень гликемии как маркер прогноза у больных инфарктом миокарда с подъемом сегмента ST. Кардиология 2012;51 (1):26–31.
  2. Deedwania P, Kosiborod M, Barrett E et al. Hyperglycemia and acute coronary syndrome: a scientific statement from the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2008 Mar 25;117 (12):1610–9.
  3. Митьковская Н. П., Данилова Л. И., Статкевич Т. В., Смирнова Е. С. Гипергликемия в остром периоде инфаркта миокарда. Медицин­ский журнал. 2009;4:67–70.
  4. Ryden L, Standl E, Bartnik M et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J. 2007;28 (1):88–136.
  5. Asadollahi K, Beeching N, Gill G. Hyperglycaemia and mortality. J R Soc Med. 2007 Nov;100 (11):503–7.
  6. Кобалава Ж. Д., Толкачева В. В. Гипергликемия у пациентов с острым коронарным синдромом: современное состояние проблемы. Научные рекомендации Комитета по сахарному диабету Американской ассоциации сердца. Кардиология 2009;49 (3):77–85.
  7. ACE / ADA Task Force on Inpatient Diabetes. American College of Endocrinology and American Diabetes Association Consensus statement on inpatient diabetes and glycemic control. Diabetes Care. 2006 Aug;29 (8):1955–62.
  8. Lavi S1, Kapeliovich M, Gruberg L et al. Hyperglycemia during acute myocardial infarction in patients who are treated by primary percutaneous coronary intervention: impact on long-term prognosis. Int J Cardiol. 2008 Jan 11;123 (2):117–22.
  9. Conaway DG, O'Keefe JH. Frequency of undiagnosed and untrea­ted diabetes mellitus in patients with acute coronary syndromes. Expert Rev Cardiovasc Ther. 2006 Jul;4 (4):503–7.
  10. Сайгитов Р. Т., Глезер М. Г. Гипергликемия как фактор риска у мужчин и женщин с острым коронарным синдромом. Проблемы женского здоровья. 2007;2 (2):14–19.
  11. Foo K, Cooper J, Deaner A et al. A single serum glucose measurement predicts adverse outcomes across the whole range of acute coronary syndromes. Heart. 2003 May;89 (5):512–6.
  12. Бацигов Х. А., Сайфутдинов Р. Г., Козлов С. В., Жернаков С. В. Стрессовая гипергликемия в оценке степени тяжести и прогноза течения инфаркта миокарда. Сибирский медицинский журнал. 2007;4:46–48.
  13. Suleiman M, Hammerman H, Boulos M et al. Fasting glucose is the important risk factor for 30‑day mortality in patients with acute myocardial infarction. A prospective study. Circulation. 2005 Feb 15;111 (6):754–60.
  14. Vivas D1, García-Rubira JC, González-Ferrer JJ et al. Prognostic value of first fasting glucose measurement compared with admission glucose level in patients with acute coronary syndrome. Rev Esp Cardiol. 2008 May;61 (5):458–64.
  15. Kosiborod M1, Inzucchi SE, Krumholz HM et al. Glucometrics in patients hospitalized with acute myocardial infarction: defining the optimal outcomes-based measure of risk. Circulation. 2008 Feb 26;117 (8):1018–27.
  16. Lipska KJ1, Venkitachalam L, Gosch K et al. Glucose variability and mortality in patients hospitalized with acute myocardial infarction. Circ Cardiovasc Qual Outcomes. 2012 Jul 1;5 (4):550–7.
  17. Krinsley JS. Glycemic variability and mortality in critically Ill patients: the impact of diabetes. J Diabetes Sci Technol. 2009 Nov 1;3 (6):1292–301.
  18. Scirica BM. Acute coronary syndrome: emerging tools for diagnosis and risk assessment. J Am Coll Cardiol. 2010 Apr 6;55 (14):1403–15.
  19. Eggers KM, Kempf T, Venge P et al. Improving long-term risk prediction in patients with acute chest pain: The Global Registry of Acute Coronary Events (GRACE) risk score is enhanced by selected nonnecrosis biomarkers. Am Heart J. 2010 Jul;160 (1):88–94.
  20. Scirica BM, Sabatine MS, Jarolim P et al. Assessment of multiple cardiac biomarkers in non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 trial. Eur Heart J. 2011 Mar;32 (6):697–705.
  21. Widera C1, Pencina MJ, Meisner A et al. Adjustment of the GRACE score by growth differentiation factor 15 enables a more accurate appreciation of risk in non-ST-elevation acute coronary syndrome. Eur Heart J. 2012 May;33 (9):1095–104.
  22. Stranders I, Diamant M, van Gelder RE et al. Admission blood glucose level as risk indicator of death after myocardial infarction in patients with and without diabetes mellitus. Arch Intern Med. 2004 May 10;164 (9):982–8.
  23. Petursson P1, Herlitz J, Caidahl K et al. Admission glycaemia and outcome after acute coronary syndrome. Int J Cardiol. 2007 Apr 4;116 (3):315–20.
  24. Sinnaeve PR1, Steg PG, Fox KA et al. Association of elevated fasting glucose with increased short-term and 6 month morta­lity in ST-Segment elevation and non-ST-Segment elevation acute coro­nary syndromes: the Global Registry of Acute Coronary Events. Arch Intern Med. 2009 Feb 23;169 (4):402–9.
Panina A. V., Dovgalevsky Ya. P., Dolotovskaya P. V. et al. Hyperglycemia at hospitalization of patients with ST-segment elevation myocardial infarction as a marker for unfavorable prognosis. Russian Heart Journal. 2014;76 (2):67–73

To access this material please log in or register

Register Authorize
Ru En